Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, September 01, 2020
Gilead Sciences announced an agreement with Jounce Therapeutics to exclusively license its JTX-1811 program.
read more
Monday, September 28, 2020
Gilead Sciences and Immunomedics have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash.
read more
Thursday, January 09, 2020
Gilead Sciences announced the company has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.
read more
Gilead Sciences has announced two appointments to the company’s senior leadership team. Kevin Young CBE has been appointed Chief Operating Officer, and Martin Silverstein, MD has been appointed Executive Vice President, Strategy.
read more
Gilead Sciences and WuXi PharmaTech have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.
read more
Monday, February 01, 2016
Gilead Sciences has announced that, effective March 10, 2016, current Chairman and CEO John C. Martin, PhD will assume the role of Executive Chairman of the company. John F. Milligan, PhD, currently President and Chief Operating Officer, will be ...
read more
Thursday, August 27, 2020
GI Partners has completed the previously announced acquisition of Clinical Ink, a global clinical trial technology company.
read more
Tuesday, November 08, 2022
Global Healthcare Opportunities, or GHO Capital Partners LLP and The Vistria Group announced that they have entered into a definitive agreement to acquire a controlling interest in Alcami Corporation from funds affiliated with Madison Dearborn ...
read more
Wednesday, December 02, 2015
GHO Capital, a European specialist healthcare investor, has announced the acquisition of Quotient Clinical, a provider of outsourced, early-stage drug development services to the pharmaceutical industry.
read more
Thursday, November 18, 2021
Global Healthcare Opportunities, or GHO Capital Partners LLP, has announced the acquisition of Genesis Research, a provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services.
read more
Wednesday, January 22, 2020
GHO has acquired Ardena, a specialist CDMO focused on early phase drug development.
read more
Friday, December 20, 2019
Getinge announced an agreement to acquire 100% of the shares in Applikon Biotechnology B.V. from Applikon Biotechnology Holding B.V.
read more
Gerresheimer announced investments to rapidly expand manufacturing, supply and logistics capacity for glass vials in the U.S. The project will be supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of ...
read more
Gerresheimer AG is planning to build a new plant in Skopje, Republic of North Macedonia.
read more
The company created bioGO in response to limited and rigid infrastructure options for launching biopharmaceutical projects.
read more